Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9936087 | 0.97 | LMNA (0.43) | LMNAHRH4HRH3CACNA2D1ADRB2 | |
| SCHEMBL15160766 | 0.97 | LMNA (0.43) | LMNAHRH4HRH3CACNA2D1ADRB2 | |
| SCHEMBL15160693 | 0.97 | LMNA (0.43) | LMNAHRH4HRH3CACNA2D1ADRB2 | |
| SCHEMBL25110753 | 0.97 | LMNA (0.43) | LMNAHRH4HRH3CACNA2D1ADRB2 | |
| SCHEMBL13884328 | 0.97 | LMNA (0.43) | LMNAHRH4HRH3CACNA2D1ADRB2 | |
| SCHEMBL23710842 | 0.97 | LMNA (0.43) | LMNAHRH4HRH3CACNA2D1ADRB2 | |
| SCHEMBL22861696 | 0.97 | LMNA (0.43) | LMNAHRH4HRH3CACNA2D1ADRB2 | |
| SCHEMBL21106768 | 0.97 | LMNA (0.43) | LMNAHRH4HRH3CACNA2D1ADRB2 | |
| SCHEMBL21401388 | 0.97 | LMNA (0.43) | LMNAHRH4HRH3CACNA2D1ADRB2 | |
| SCHEMBL7861357 | 0.97 | LMNA (0.43) | LMNAHRH4HRH3CACNA2D1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226226-A1 | KAPPA-OPIOID RECEPTOR AGONIST IMPLANTS FOR TREATMENT OF PRURITUS | TITAN PHARMACEUTICALS INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226226-A1 | KAPPA-OPIOID RECEPTOR AGONIST IMPLANTS FOR TREATMENT OF PRURITUS | TITAN PHARMACEUTICALS INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-16 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-2809660-B1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORP (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION | 2015-01-01 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| WO-2013116682-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20100016289-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2009-04-30 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | IL17A, IL15, IL2 | LMNA 4105/4885HRH4 2388/4885HRH3 3459/4885 |
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | LMNA 2444/4885HRH4 4071/4885HRH3 3387/4885 |
| US-20100016289-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | LMNA 4072/4885HRH4 109/4885HRH3 182/4885 |
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNB1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNY | LMNA 1304/4885HRH4 503/4885HRH3 832/4885 |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | LMNA 4613/4885HRH4 681/4885HRH3 1089/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | LMNA 341/4885HRH4 4555/4885HRH3 3548/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | LMNA 2270/4885HRH4 2846/4885HRH3 2319/4885 |
| US-20240226226-A1 | KAPPA-OPIOID RECEPTOR AGONIST IMPLANTS FOR TREATMENT OF PRURITUS | OPRK1, OPRL1, OPRD1 | LMNA 4772/4885HRH4 71/4885HRH3 58/4885 |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | FAAH, FAAH2, EPHX2 | LMNA 4459/4885HRH4 197/4885HRH3 230/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885HRH4 3886/4885HRH3 3631/4885 |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | LMNA 2009/4885HRH4 4234/4885HRH3 4414/4885 |
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | LMNA 2481/4885HRH4 3532/4885HRH3 3236/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885HRH4 3886/4885HRH3 3631/4885 |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | LMNA 617/4885HRH4 276/4885HRH3 316/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | LMNA 4613/4885HRH4 681/4885HRH3 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.